Case Report | Volume: 7, Issue: 1, January, 2017
Case Report | Volume: 7, Issue: 1, January, 2017
Penfluridol is a long acting oral antipsychotic agent taken once a week for the treatment of schizophrenia and other psychotic disorders. The weekly dosage regimen of the drug makes it an ideal drug in non-compliant patients, which is commonly seen in 50-75% of psychotic disorder patients. Better compliance may be associated with fewer relapses, better quality of life, fewer crises and less or shorter hospitalizations, leading to lower costs. As a part of pharmacovigilance program of India, we hereby report a case of Penfluridol induced extrapyramidal symptoms in a patient with refractory schizophrenia who developed EPS even at the least possible dose of the drug. Relevant data was collected from case record as per Central Drug Standard Control Organisation form and causality, severity and preventability assessment was done as per Naranjo’s, Hartwigs and Schumock and Thornton scales respectively.
Thomson SR, Ommurugan B, Adiga S, Patil N, Reddy S. Penfluridol Induced Extrapyramidal symptoms (EPS): A Case Report. J App Pharm Sci, 2017; 7 (01): 214-216.
Year
Month